First Western Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

First Western Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-35,350	Closed	-$1.59M	–	115
2015 Q2	$1.59M	Buy	+35,350	New	+$1.38M	0.51%	83

Other funds holding ENTA

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

First Western Capital Management's ENTA Position: Q3 2015 in Review

First Western Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2015, closing a stake of 35,350 shares — an estimated $1.59M sold.

First Western Capital Management first reported a position in ENTA in Q2 2015 and held it in 1 quarter. The position peaked at $1.59M in Q2 2015. 144 funds tracked by Wall St. Rank hold ENTA as of Q3 2015.

First Western Capital Management reported no remaining Enanta Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
First Western Capital Management sold 35,350 Enanta Pharmaceuticals shares in Q3 2015, an estimated $1.59M.
First Western Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 1 quarter.
First Western Capital Management's Enanta Pharmaceuticals position peaked at $1.59M in Q2 2015.
144 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2015.

Based on First Western Capital Management's 13F filing for Q3 2015, filed 20 Oct 2015.